{"schema_version":"secwatch.filing_event.v1","accession":"0001510964-23-000036","form_type":"8-K","ticker":"CVSI","cik":"0001510964","company_name":"CV Sciences, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.314360+00:00","generated_at":"2026-06-08T03:28:54.232010+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CV Sciences Q3 revenue $4.1M (+9% YoY); margin expands; signs LOI for European acquisition","bullets":["Revenue $4.1M, +9% YoY from $3.8M; gross margin 45.1% vs 41.6%.","Operating loss narrowed to $0.4M from $0.9M; adjusted EBITDA -$0.4M vs -$1.2M.","Cash balance $1.6M (up from $0.6M end 2022); operating cash flow $2.4M (incl. $2.5M ERC).","Signed non-binding LOI to acquire a plant-based food company in Europe as part of new M&A strategy.","Maintained #1 hemp extract brand in natural retail; launched PlusCBD Reserve Sleep Gummies."],"urls":{"canonical":"https://secwatch.observer/filing/0001510964-23-000036","json":"https://secwatch.observer/filing/0001510964-23-000036.json","markdown":"https://secwatch.observer/filing/0001510964-23-000036.md","text":"https://secwatch.observer/filing/0001510964-23-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1510964/000151096423000036/0001510964-23-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1510964/000151096423000036/cvsi-20231114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:28:54.232010+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"164ec86593cf621a066cfde16cffc6169393e286","claim":"CV Sciences, Inc. reported the quarter ended September 30, 2023 results: revenue $4.1 million.","evidence_excerpt":"products, today announced its financial results for the quarter ended September 30, 2023. Third Quarter 2023 and Recent Financial and Operating Highlights • Increased revenue to $4.1 million for the third quarter 2023 compared to $3.8 million for third quarter 2022 and a sequential improvement from $4.0 million for the second quarter 2023; • Recognized gross margin","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1510964/000151096423000036/0001510964-23-000036-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$4.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}